



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/165, 31/215, C07C 237/20, 233/33, 323/60</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/33457</b> <b>(43) International Publication Date:</b> 14 December 1995 (14.12.95)
<b>(21) International Application Number:</b> PCT/US95/07187 <b>(22) International Filing Date:</b> 6 June 1995 (06.06.95) <b>(30) Priority Data:</b> 08/254,090 6 June 1994 (06.06.94) US <b>(71) Applicant:</b> ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134 (US). <b>(72) Inventors:</b> YANNI, John, M.; 2821 Donnybrook Drive, Burleson, TX 76028 (US). GRAFF, Gustav; Route 4, Box 729 E, Cleburne, TX 76031 (US). HELLBERG, Mark, R.; 5211 Override Drive, Arlington, TX 76017 (US). <b>(74) Agents:</b> RYAN, Patrick, M. et al.; Alcon Laboratories, Inc., Patent Dept. Q-148, 6201 South Freeway, Fort Worth, TX 76134 (US).		<b>(81) Designated States:</b> AU, CA, CN, JP, KR, MX, SG, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS  <b>(57) Abstract</b>  Novel ester and amide derivatives of 3-benzoylphenylacetic acid are disclosed. The use of these novel derivatives and certain known derivatives in topically administrable compositions for the treatment of ophthalmic inflammatory disorders is also disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AT</b>	Austria	<b>GB</b>	United Kingdom	<b>MR</b>	Mauritania
<b>AU</b>	Australia	<b>GE</b>	Georgia	<b>MW</b>	Malawi
<b>BB</b>	Barbados	<b>GN</b>	Guinea	<b>NE</b>	Niger
<b>BE</b>	Belgium	<b>GR</b>	Greece	<b>NL</b>	Netherlands
<b>BF</b>	Burkina Faso	<b>HU</b>	Hungary	<b>NO</b>	Norway
<b>BG</b>	Bulgaria	<b>IE</b>	Ireland	<b>NZ</b>	New Zealand
<b>BJ</b>	Benin	<b>IT</b>	Italy	<b>PL</b>	Poland
<b>BR</b>	Brazil	<b>JP</b>	Japan	<b>PT</b>	Portugal
<b>BY</b>	Belarus	<b>KE</b>	Kenya	<b>RO</b>	Romania
<b>CA</b>	Canada	<b>KG</b>	Kyrgystan	<b>RU</b>	Russian Federation
<b>CF</b>	Central African Republic	<b>KP</b>	Democratic People's Republic of Korea	<b>SD</b>	Sudan
<b>CG</b>	Congo	<b>KR</b>	Republic of Korea	<b>SE</b>	Sweden
<b>CH</b>	Switzerland	<b>KZ</b>	Kazakhstan	<b>SI</b>	Slovenia
<b>CI</b>	Côte d'Ivoire	<b>LI</b>	Liechtenstein	<b>SK</b>	Slovakia
<b>CM</b>	Cameroon	<b>LK</b>	Sri Lanka	<b>SN</b>	Senegal
<b>CN</b>	China	<b>LU</b>	Luxembourg	<b>TD</b>	Chad
<b>CS</b>	Czechoslovakia	<b>LV</b>	Latvia	<b>TG</b>	Togo
<b>CZ</b>	Czech Republic	<b>MC</b>	Monaco	<b>TJ</b>	Tajikistan
<b>DE</b>	Germany	<b>MD</b>	Republic of Moldova	<b>TT</b>	Trinidad and Tobago
<b>DK</b>	Denmark	<b>MG</b>	Madagascar	<b>UA</b>	Ukraine
<b>ES</b>	Spain	<b>ML</b>	Mali	<b>US</b>	United States of America
<b>FI</b>	Finland	<b>MN</b>	Mongolia	<b>UZ</b>	Uzbekistan
<b>FR</b>	France			<b>VN</b>	Viet Nam
<b>GA</b>	Gabon				

**Topically Administrable Compositions Containing**  
**3-Benzoylphenylacetic Acid Derivatives for Treatment**  
**of Ophthalmic Inflammatory Disorders**

**Field of the Invention**

5 This invention relates to topically administrable compositions for the treatment of inflammatory disorders. In particular, this invention relates to non-irritating, topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for the treatment of ophthalmic inflammatory disorders.

**Background of the Invention**

10 3-benzoylphenylacetic acid and certain of its derivatives are known to possess anti-inflammatory activity. U.S. Patent Nos. 4,254,146, 4,045,576, 4,126,635, and 4,503,073, and U.K. Patent Application Nos. 2,071,086A and 2,093,027A teach various 3-benzoylphenylacetic acids, salts and esters, and hydrates thereof, having anti-inflammatory activity. U.S. Patent No. 4,568,695 teaches 2-amino-3-benzoylphenylethyl alcohols having  
15 anti-inflammatory activity. U.S. Patent No. 4,313,949 teaches 2-amino-3-benzoylphenylacetamides having anti-inflammatory activity.

Each of the above-listed patents or patent applications, all of which are assigned in whole or in part to A. H. Robins, contains an identical disclosure regarding formulations of the 3-benzoylphenylacetic acid or acid derivative. Each of the above also contains the same  
20 disclosure regarding administration routes for the drug formulation. The only formulation examples in the A. H. Robins patents or patent applications are capsules, tablets and "injectable—2% sterile solutions," and the only administration routes mentioned are oral (as in capsules or tablets) parenteral (in the form of sterile solutions or suspensions), and, in some cases intravenous (in the form of sterile solutions). No topical or local  
25 administration is taught by any of the above-listed patents or patent applications.

Certain derivatives of 2-amino-3-benzoylbenzeneacetic acid (amfenac) and 2-amino-3-(4-chloro-benzoyl)benzeneacetic acid have also been evaluated by Walsh et al., J. Med. Chem., 33:2296-2304 (1990), in an attempt to discover nonsteroidal anti-inflammatory prodrugs with minimal or no gastrointestinal side effects upon oral administration.

In contrast, U.S. Patent No. 4,683,242 teaches the transdermal administration of 2-amino-3-benzoylphenylacetic acids, salts, and esters, and hydrates and alcoholates thereof to control inflammation and alleviate pain.

U.S. Patent No. 4,910,225 teaches certain benzoylphenylacetic acids for local administration to control ophthalmic, nasal or otic inflammation. Only acetic acids are disclosed in the '225 patent; no esters or amides are mentioned or taught as anti-inflammatory agents for local administration to the eyes, nose and ears.

Although benzoylphenylacetic acids are effective in suppressing ocular inflammation, their full anti-inflammatory potential has not yet been approached due to their generally slow rate of penetration through the cornea. Relatively high concentrations of these drugs are often needed to achieve corneal penetration rates sufficient to provide effective intraocular drug concentrations. Such high drug concentrations are generally not desirable as they may provoke ocular irritation and discomfort.

Additionally, the acetic acid compounds taught in the '225 patent are difficult to formulate in stable aqueous solutions. The '225 patent solves this problem by incorporating a water-soluble polymer and sulfite, and adjusting the pH to about 6.0 to 9.0, preferably about 7.5-8.5. Water soluble polymers taught by the '225 patent include polyvinyl pyrrolidone, carboxypropylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, sodium salt of polyacrylic acid and so on. Polyvinyl pyrrolidone is preferred. The concentration of water soluble polymer is in the range of 0.1 to 10 w/w%. Sulfite includes sodium, potassium, magnesium, and calcium sulfite salt and so on. The concentration is in the range of about 0.1 to 1.0 w/w %.

What is needed are additional non-steroidal, topically administrable anti-inflammatory agents which are stable, non-irritating at therapeutic doses, and at least as potent as benzoylphenylacetic acids in suppressing ocular inflammation.

### **Summary of the Invention**

5 It has now been found that certain novel and certain known 3-benzoylphenylacetic acid derivatives are useful as topically administrable anti-inflammatory compounds for treating ophthalmic inflammatory disorders. Converting the free acetic acid functional group to an ester or an amide enhances compound stability by slowing the rate of lactam formation. Among other factors, the present invention is based on the finding that certain  
10 3-benzoylphenylacetic acid derivatives which show no significant anti-inflammatory activity in vitro are, in fact, as active or even more active than the parent 3-benzoylphenylacetic acids when administered topically to the eye.


Accordingly, the present invention is directed to novel derivatives of 3-benzoylphenylacetic acid compounds. The present invention is also directed to  
15 pharmaceutical compositions suitable for topical ophthalmic administration which contain an anti-inflammatory-effective amount of a 3-benzoylphenylacetic acid derivative, and to a method of treating ophthalmic inflammatory disorders which comprises topically administering to the eye a 3-benzoylphenylacetic acid derivative.

### **Detailed Description of the Invention**

20 As used herein, "(un)branched" means optionally branched, and "(un)substituted" means optionally substituted.

The novel 3-benzoylphenylacetic acid derivative compounds of the present invention have the following structural formula:

(I)



W = O, H

R = H, C<sub>1-4</sub>(un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>

Y = OR<sup>5</sup>, NR<sup>5</sup>R<sup>6</sup>

R<sup>5</sup> = -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>2</sup>-(CH<sub>2</sub>)<sub>r</sub>A, -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>3</sup>-(CH<sub>2</sub>)<sub>r</sub>A'

r=2-6

r'=0-6

Z<sup>2</sup> = O, C=O, OC(=O), C(=O)NR<sup>3</sup>, NR<sup>3</sup>C(=O), -S(O)<sub>n2</sub>CH<sub>2</sub>-, S, CHOR<sup>3</sup>, NR<sup>3</sup>

Z<sup>3</sup> = nothing, -CHR<sup>4</sup>-, -CR<sup>4</sup>R<sup>4</sup>-

r<sup>2</sup>=1, 2

R<sup>3</sup>=H, C<sub>1-6</sub>(un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

A = H, OH, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle, -(CH<sub>2</sub>)<sub>r</sub>OR<sup>3</sup>

A' = OH, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH<sub>2</sub>)<sub>r</sub>OR<sup>3</sup>

R<sup>4</sup> = C<sub>1-6</sub>(un)branched alkyl

R<sup>6</sup> = H, OR<sup>7</sup>

R<sup>7</sup> = H, C<sub>1-6</sub>(un)branched alkyl, (un)substituted aryl (substitution as defined by X below)

X and X' independently = H, F, Cl, Br, I, OR<sup>7</sup>, CN, OH, S(O)<sub>n2</sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>, NO<sub>2</sub>

m = 0-3

m' = 0-5

n<sup>2</sup> = 0-2

The preferred, novel 3-benzoylphenylacetic acid derivatives are those wherein:

W = H

R = H, CH<sub>3</sub>

Y = NR<sup>5</sup>R<sup>6</sup>, -NHOH

5 R<sup>4</sup> = C<sub>1-4</sub> (un)branched alkyl

R<sup>5</sup> = -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>2</sup>-(CH<sub>2</sub>)<sub>r</sub>-A, -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>3</sup>-(CH<sub>2</sub>)<sub>r</sub>-A'

r = 2-4

r' = 0-2

Z<sup>2</sup> = O

10 Z<sup>3</sup> = nothing

A = H

A' = (un)substituted aryl (substitution as defined by X below)

R<sup>6</sup> = H, OR<sup>7</sup>

R<sup>7</sup> = H, C<sub>1-2</sub> alkyl


15 X and X' independently = H, F, Cl, Br, CF<sub>3</sub>, S(O)<sub>n2</sub>R<sup>4</sup>, OR<sup>7</sup>

m = 0-2

m' = 0-3

n<sup>2</sup> = 0

20 The 3-benzoylphenylacetic acid derivative compounds useful in the topically administrable ophthalmic compositions of the present invention are represented by the following structural formula which includes both known derivatives and the novel derivatives of the present invention:



(I)

R = H, C<sub>1-4</sub> (un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>

Y = OR'; NR''R'

R' = H (except when Y = OR'), C<sub>1-10</sub> (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -

(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A

n = 2-6

n' = 1-6

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR<sup>3</sup>, NR<sup>3</sup>C(=O), S(O)<sub>n2</sub>, CHOR<sup>3</sup>, NR<sup>3</sup>

n<sup>2</sup> = 0-2

R<sup>3</sup> = H, C<sub>1-6</sub> (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH<sub>2</sub>)<sub>n</sub>OR<sup>3</sup>

R'' = H, OH, OR'

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)<sub>n2</sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>, NO<sub>2</sub>

R<sup>4</sup> = C<sub>1-6</sub> (un)branched alkyl

m = 0-3

m' = 0-5

W = O, H

Preferred compounds for use in the pharmaceutical compositions or method of the present invention are those of Formula I wherein:

R = H, C<sub>1-2</sub> alkyl

Y = NR'R''

R' = H, C<sub>1-6</sub> (un)branched alkyl, -(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A

Z = nothing, O, CHOR<sup>3</sup>, NR<sup>3</sup>

R<sub>3</sub> = H

A = H, OH, (un)substituted aryl (substitution as defined by X below)

X and X' independently = H, F, Cl, Br, CN, CF<sub>3</sub>, OR', SR<sup>4</sup>, R<sup>4</sup>

R'' = H

R<sup>4</sup> = C<sub>1-4</sub> (un)branched alkyl



$m = 0-2$

$m' = 0-2$


$W = H$

$n = 2-4$

$n' = 0-3$


The most preferred compounds for use in the compositions or method of the present invention are 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide; and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

The preparation of the compounds of Formula I, Formula VII and Formula IX may be accomplished by the reactions outlined in the following scheme:




wherein X, Y, R, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, m, m', and W are as defined above. The general method for the preparation for compounds of Formula I and Formula IV where Y is such that the compound is an amide derivative and W is hydrogen are detailed in U.S. Patent 4,313,949 assigned to A. H. Robins. The general method for preparing compounds of Formula V and detailing the conversion of compounds of Formula V into compounds of the Formula VII are described in U.S. Patent Nos. 4,045,576, 4,503,073, 4,182,774, and 4,126,635 all assigned to A. H. Robins, and by the methods of Walsh et al., (J. Medicinal Chemistry, volume 27, 1984, pages 1379-88 and J. Medicinal Chemistry, volume 33, 100, pages 2296-2304). Compounds of Formula VI where X' is a suitable leaving group such as Cl, Br, I, or organic sulfonate (mesylate, tosylate) and R<sup>5</sup> is as described above, may be prepared by one skilled in the art. Amides of Formula IX may be formed by reacting esters of Formula VII (preferably ethyl or methyl esters) with the appropriate amine of Formula VIII either neat or in the presence of a solvent such as dimethyl formamide, dimethyl sulfoxide or acetonitrile at temperatures between 0 and 150°C. Amines of Formula VIII, may be prepared by one skilled in the art.

The synthesis of compounds of Formula I and the carboxylic acid of Formula X where W is oxygen is detailed in U.S. Patent 4,254,146 assigned to A. H. Robins and is outlined below. The required amine or alcohol (Formula XI) is commercially available or can be readily prepared by one skilled in the art.




The manipulation of suitable protecting groups and deprotecting steps as employed by one skilled in the art may be necessary for the preparation of compounds of Formula I, Formula IV, Formula VIII, Formula IX and required intermediates.


The invention will be further illustrated by the following examples which are intended to be illustrative, but not limiting.




Compound 1  
2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide




Compound 2  
2-Amino-3-benzoyl- $\alpha$ -(n-propylthio)-phenylacetamide




Compound 3  
2-Amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide




Compound 4  
2-Amino-3-benzoyl-5-chloro- $\alpha$ -(methylthio)-phenylacetamide




Compound 5  
2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(methylthio)-N-(2-methoxy)ethyl acetamide



Compound 6  
2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(methylthio)-N-3-(3,4-dimethoxyphenyl)propyl phenylacetamide




Compound 7  
2-Amino-3-(4-fluorobenzoyl)-phenylacetamide




Compound 8  
2-Amino-3-benzoyl-phenylacetamide


11




Compound 9  
2-Amino-3-(4-chlorobenzoyl)-phenylacetamide




Compound 10  
2-Amino-3-benzoyl-5-chlorophenylacetamide




Compound 11  
2-Amino-3-(4-fluorobenzoyl)-N-(2-methoxy)ethyl phenylacetamide




Compound 12  
2-Amino-3-(4-fluorobenzoyl)-N-3-(3,4-dimethoxyphenyl)propyl phenylacetamide




Compound 13  
3-Benzoyl-2-nitrophenyl-N-3-(3,4-dimethoxyphenyl)propyl acetamide



Compound 14  
Ethyl 2-amino-3-(4-bromobenzoyl)-benzene acetate



Compound 15  
2-Amino-3-(4-bromobenzoyl)-phenylacetamide



Compound 16  
2-Amino-3-(4-bromobenzoyl)-N-methyl-phenylacetamide

**Preparation I****2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, Compound 1**

A solution of 21.5 g (0.1 mole) of 4'-fluoro-2-aminobenzophenone in 400 mL of methylene chloride was cooled to -70° C and 11.5 g (0.1 mole) of 95% t-butylhypochlorite was added over a period of 15 min, keeping the temperature below -66° C. To this solution was added a solution of 13.3 g of 2-n-propylthioacetamide in 50 mL of methylene chloride over a 10 min period. The solution was stirred for 1 h at -65 to -70° C and then allowed to warm to 0° C at which point 10.2 g (0.1 mole) of triethylamine was added. The solution was stirred for 10 min and then washed with water. The organic solution was dried over magnesium sulfate. After concentrating under reduced pressure, the residue was crystallized from isopropyl alcohol and dried to give 19.5 g (56%) of yellow crystals melting at 140-142° C.

Analysis: Calculated for  $C_{18}H_{19}N_2O_2SF$ : C, 62.41; H, 5.53; N, 8.09. Found: C, 62.34; H, 5.58; N, 8.04.

**Preparation II****2-Amino-3-benzoyl- $\alpha$ -(n-propylthio)-phenylacetamide, Compound 2**

In the same manner as given in Preparation I, 2-amino-3-benzoyl- $\alpha$ -(n-propylthio)-phenylacetamide, Compound 2, is prepared from 2-aminobenzophenone, t-butylhypochlorite and 2-n-propylthioacetamide.

**Preparation III****2-Amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, Compound 3**

In the same manner as given in Preparation I, 2-amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, Compound 3, is prepared from 4'-chloro-2-aminobenzophenone, t-butylhypochlorite and 2-n-propylthioacetamide.

**Preparation IV**

2-Amino-3-benzoyl-5-chloro- $\alpha$ -(methylthio)-phenylacetamide, Compound 4

To a cold (-70° C) solution of 12.77 g (0.055 mole) of 2-amino-5-chlorobenzophenone in 300 mL of methylene chloride, under nitrogen atmosphere, was added 6.0 g (0.552 mole) of t-butylhypochlorite in 20 mL of methylene chloride. After the reaction was stirred for  
5 an additional 15 min, a suspension of 5.8 g (0.055 mole) of  $\alpha$ -(methylthio)acetamide in 150 mL of methylene chloride was added. The mixture was stirred at -65° C for 1 h. Triethylamine (5.6 g, 0.055 mole) was added and the solution was allowed to warm to room temperature. The reaction mixture was extracted with water and the organic layer dried over magnesium sulfate. The volume of the solution was reduced in vacuo to about  
10 200 mL and the product crystallized as a yellow solid, m.p. 173.5-174.5° C. Yield was 6.86 g (37.3%).

Analysis: Calculated for  $C_{16}H_{15}N_2O_2SCl$ : C, 57.40; H, 4.52; N, 8.36. Found C, 57.38; H, 4.50; n, 8.51

## Preparation V

2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(methylthio)-N-(2-methoxy)ethylacetamide, Compound 5

To a solution of 21.5 g (0.1 mole) of 2-amino-4'-fluoro-benzophenone in 400 mL of methylene chloride cooled to -70° C is added 11.5 g (0.1 mole) of 95% t-butylhypochlorite over 15 min, keeping the temperature below -66° C. To this solution is  
20 added a solution of  $\alpha$ -(methylthio)-N-(2-methoxyethyl)acetamide (0.1mole) in 50 mL of methylene chloride over a ten minute period. The solution is stirred for 1 h at -65 to -70° C and then is allowed to warm to 0° C. Triethylamine (0.1 mole) is added and the resulting solution is washed with water. The organic solution is dried with magnesium sulfate, and concentrated in vacuo. The product is isolated using standard conditions.

## Preparation VI

2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(methylthio)-N-3-(3,4-dimethoxyphenyl)propyl acetamide, Compound 6



To a solution of 21.5 g (0.1 mole) of 2-amino- 4'-fluoro-benzophenone in 400 mL of methylene chloride, cooled to -70° C is added 11.5 g (0.1 mole) of 95% t-butyldichlorite over 15 min, keeping the temperature below -66° C. To this solution is added a solution of  $\alpha$ -(methylthio)-N-3-(3,4-dimethoxyphenyl)propylacetamide (0.1 mole) in 50 mL of methylene chloride over a ten minute period. The solution is stirred for 1 h at -65 to -70° C and then is allowed to warm to 0° C. Triethylamine (0.1 mole) is added and the resulting solution is washed with water. The organic solution is dried with magnesium sulfate, and concentrated in vacuo. The product is isolated using standard conditions.

## Preparation VII

### 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, Compound 7

A solution of 24.2 g (0.07mole) of 2-amino-3-(4-fluorobenzoyl)- $\alpha$ -(n-propylthio)phenylacetamide in 300 mL of tetrahydrofuran was treated with an excess of wet Raney nickel (washed three times with water and three times with tetrahydrofuran). The mixture was stirred for 1 h and filtered. The filtrate was concentrated under reduced pressure and the residue was crystallized from 95% ethanol to afford 14.8 g (78%) of yellow needles melting at 184-186° C.

Analysis: Calculated for  $C_{15}H_{13}N_2O_2F$ : C, 66.17; H, 4.81; N, 10.29. Found: C, 66.32; H, 4.81; N, 10.48.

**Preparation VIII****2-Amino-3-benzoyl-phenylacetamide, Compound 8**

In the same manner as given in Preparation VII, 2-amino-3-benzoyl-phenylacetamide is prepared from 2-amino-3-benzoyl- $\alpha$ -(n-propylthio)-phenylacetamide.

**5 Preparation IX****2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, Compound 9**

In the same manner as given in Preparation VII, 2-amino-3-(4-chlorobenzoyl)-phenylacetamide is prepared from 2-amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide.

**10 Preparation X****2-Amino-3-benzoyl-5-chlorophenylacetamide, Compound 10**

A mixture of 21.34 g (0.0639 mole) of 2-amino-benzoyl-5-chloro- $\alpha$ -(methylthio)-phenylacetamide and excess Raney nickel in a mixture of 900 mL absolute ethanol, and 200 mL dimethylformamide was stirred at room temperature for 45 min. The mixture was  
**15** filtered through celite to remove Raney nickel. The solvent was removed under reduced pressure to give a yellow solid which was recrystallized to give a solid, m.p. 213.5-215.0° C (d).

Analysis: Calculated for  $C_{15}H_{13}N_2O_3Cl$ : C, 62.40; H, 4.54; N, 9.70. Found: C, 62.35; H, 4.58; N, 9.74.

**20 Preparation XI****2-Amino-3-(4-fluorobenzoyl)-N-(2-methoxy)ethyl phenylacetamide, Compound 11**

A mixture of 0.07 mole of 2-amino-3-(4-fluorobenzoyl)- $\alpha$ -(methylthio)-N-(2-methoxy)ethylacetamide in 300 mL of tetrahydrofuran is treated with an excess of wet Raney nickel (washed three times with water and three times with tetrahydrofuran). The

mixture is stirred for 1 h and filtered. The filtrate is concentrated under reduced pressure and the residue is purified by standard procedures to give the product.

#### Preparation XII

2-Amino-3-(4-fluorobenzoyl)-N-3-(3,4-dimethoxyphenyl)propyl phenylacetamide,

5 Compound 12

A mixture of 0.07 mole 2-amino-3-(4-fluorobenzoyl)- $\alpha$ -(methylthio)-N-3-(3,4-dimethoxyphenyl)propylacetamide in 300 mL of tetrahydrofuran is treated with an excess of wet Raney nickel (washed three times with water and three times with tetrahydrofuran). The mixture is stirred for 1 h and filtered. The filtrate is concentrated under reduced  
10 pressure and the residue is purified by standard procedures to give the product.

#### Preparation XIII

3-Benzoyl-2-nitrophenyl-N-3-(3,4-dimethoxyphenyl)propyl acetamide, Compound 13

A mixture of 0.028 mole of 3-benzoyl-2-nitrobenzeneacetic acid, 50 mL of thionyl chloride and 50 mL of benzene is heated at reflux. The dark solution is concentrated  
15 under vacuum. The residue is diluted with benzene and concentrated under vacuum (twice). A portion of the acid chloride (0.013 mole) in tetrahydrofuran is added to a solution of 3-amino (3,4-dimethoxyphenyl)propane (0.015 mole). The mixture is stirred at room temperature and then added to 200 mL of cold water. The resulting mixture is extracted with diethyl ether. The combined extracts are washed with water, dried over  
20 sodium sulfate and concentrated under reduced pressure. The residue is purified using standard procedures to give the product.

## Preparation XIV

Ethyl-2-Amino-3-(4-bromobenzoyl)benzene acetate, Compound 14

A slurry of 35.6 g (0.1 mole) of 2-amino-3-(bromobenzoyl)benzeneacetic acid in 500 mL of dimethylformamide was treated with 32.0 g (0.2 mole) of ethyl iodide and stirred at ambient temperature for 24 h. The mixture was filtered and the filtrate was poured into 3.5 l of water. The solid which precipitated was collected by filtration, washed with water and recrystallized from absolute ethanol to give 26.8 g (74%) of the title compound, as gold needles, m.p. 107-109° C.

Analysis: Calculated for  $C_{17}H_{16}BrNO_3$ : C, 56.37; H, 4.45; N, 3.87. Found: C, 56.22; H 4.42; N, 3.87.

## Preparation XV

2-Amino-3-(4-bromobenzoyl)-phenylacetamide, Compound 15

Ammonia is condensed in a tube containing 2-amino-3-(4-bromobenzoyl)benzeneacetic acid, ethyl ester. The tube is sealed and the reaction mixture is warmed. The sealed tube was cooled and opened. Solvent was evaporated and the residue was purified by standard methods to give Compound 15.

## Preparation XVI

2-Amino-3-(4-bromobenzoyl)-N-methyl phenylacetamide, Compound 16

In the same manner as Preparation XV, 2-amino-3-(4-bromobenzoyl)-N-methyl phenylacetamide, Compound 16 is prepared from 2-amino-3-(4-bromobenzoyl)benzeneacetic acid, ethyl ester and methylamine.

## Anti-Inflammatory Tests

### I. In vitro Anti-Inflammatory Test

In vitro anti-inflammatory activity of 2-amino-3-benzoylbenzeneacetic acid analogues was tested by polarographically monitoring the inhibition in the rate of oxygen consumption (Cook HW., Ford G., and Lands WEM, Anal. Biochem. 96:341, 1979) in the conversion of arachidonic acid to prostaglandin H<sub>2</sub> by prostaglandin H synthase (cyclooxygenase). Cyclooxygenase enzyme was prepared by solubilizing 20 mg of lipid-depleted sheep vesicular gland microsomal powder (Graff G, Stephenson JH, et al., J. Biol. Chem. 253:7662, 1978) in 1.0 mL of buffer containing 50 mM phosphate, 5 mM diethyldithiocarbamic acid, and 2  $\mu$ M hematin (pH 7.4). Incubations were carried out at 30°C with a YSI-oxygen monitor (Model 53) in 50 mM phosphate/0.5 mM phenol buffer (pH 7.4) as described elsewhere (Graff G, and Anderson LA, Prostaglandins 38:473, 1989).

### II. Ex Vivo Anti-Inflammatory Test

Ex vivo anti-inflammatory activity of 2-amino-3-benzoylbenzeneacetic acid analogues was evaluated in naive New Zealand Albino (NZA) rabbits. In this test animals were dosed bilaterally with a single 50  $\mu$ L aliquot of a 0.1 % solution/suspension of vehicle, formulated test or reference compound. After 60 minutes of treatment, animals were euthanized, iris/ciliary body (ICB) quickly excised and placed into ice-cold PBS buffer (pH 7.4). The tissue was then weighed, homogenized in ice-cold 50 mM phosphate/0.5 mM phenol buffer (pH 7.4) and incubated for 10 minutes at 37°C with 10  $\mu$ M of [1-<sup>14</sup>C]-20:4. Upon termination of the incubations, reaction products (prostaglandins) were isolated by organic solvent extraction (Bligh, E.G. and Dyer, W.J., Can. J. Biochem. Physiol. 37:911, 1959) and quantified by C<sub>18</sub>-HPLC (Powell, W.S., Anal. Biochem. 148:59 1985).

### III. In Vivo Anti-Inflammatory Test

In vivo anti-inflammatory activity of 2-amino-3-benzoylbenzeneacetic acid analogues was evaluated in the model of trauma-induced breakdown of the blood-aqueous-barrier in New Zealand Albino (NZA) rabbits. Animals were anesthetized prior to bilateral administration of a single topical 50  $\mu$ L dose of a 0.1 % solution/ suspension of formulated test or reference compound. After 45 minutes of treatment ocular trauma was induced by paracentesis. Thirty minutes post-paracentesis animals were euthanized, and aqueous humor was removed for protein (Bradford MM, Anal. Biochem. 72:248, 1976) and PGE<sub>2</sub> analysis (Radio immune assay, NEN-Research Products, E.I. Du Pont de Nemours, Boston, MA).

#### Results

The results from in vitro, ex vivo and in vivo anti-inflammatory tests are summarized in Table 1. Non-halogenated and halogenated 2-amino-3-benzoylbenzeneacetic acid analogues with free carboxylic acid functional groups, including the reference compound diclofenac, were potent in vitro inhibitors of sheep vesicular gland cyclooxygenase activity with IC<sub>50</sub> values ranging from 0.029 to 0.250  $\mu$ M. When tested in vivo, they effectively inhibited trauma-induced accumulation of PGE<sub>2</sub> ( $\geq$  98 %) and plasma protein influx into the aqueous humor in vivo. Similar results were obtained with the reference compound, diclofenac, which was somewhat less effective both in vitro and in vivo than the chloro- or bromo- substituted 2-amino-3-benzoylbenzeneacetic acids.

In contrast, unsubstituted and mono-substituted amide analogues of 2-amino-3-benzoylbenzeneacetic acid (Compounds 7, 8, 9, 15 and 16) were  $\geq$  3 orders of magnitude less effective inhibitors of cyclooxygenase activity in vitro with IC<sub>50</sub> values ranging from 16 to  $>133$   $\mu$ M. Despite their weak inhibitory effects on cyclooxygenase activity in vitro, they were as effective as, or in one instance (Compound 7) more effective than, free carboxylic acid analogues in inhibiting plasma protein influx into the anterior chamber (62 to 72 %) and aqueous humor PGE<sub>2</sub> accumulation ( $>93$  %). Interestingly, the dimethyl substituted amide analog was inactive in both in vitro and in vivo tests.

Although the in vitro potency was clearly enhanced by halogenation of the 4-position of the benzoyl ring of 2-amino-3-benzoylbenzeneacetic acid, there was little evidence for such a structure related effect in vivo.

When tested for ex vivo anti-inflammatory activity, Compound 8 was the most effective inhibitor of iris/ciliary body prostaglandin synthesis. The synthesis of all prostaglandins produced by the iris/ciliary body was inhibited to a similar extent. This spectrum of inhibition is in contrast to the effects of 2-amino-3-benzoylbenzeneacetic acid analogs with free carboxylic acid functional groups which predominately inhibited PGE<sub>2</sub> production.

Conversion of the free carboxylic acid functional group of Bromfenac to an ethyl ester (Compound 14) also resulted in a >3 orders of magnitude decline in in vitro cyclooxygenase inhibitory activity. However, when tested for topical ocular anti-inflammatory activity the ethyl ester showed significant inhibitory activity by reducing plasma protein extravasation into the aqueous humor by 60 %.




TABLE 1

## SUMMARY OF ANTI-INFLAMMATORY TEST RESULTS

Compound	Substituent	Y	In Vitro Cyclooxygenase Inhibition IC50 (uM)	Ex Vivo Iris/Ciliary Body Total Prostaglandin Synthesis Inhibition (%)***	In Vivo Aqueous Humor PGE2 Accumulation Inhibition (%)*	In Vivo Paracentesis Protein Extravasation Inhibition (%)*
Diclofenac**	-	-	0.120	50	97	54
Amfenac	4'-H	OH	0.25	-	-	41
-	4'-F	OH	0.171	-	-	42
-	4'-Cl	OH	0.070	-	99	72
Bromfenac	4'-Br	OH	0.029	44	98	62
# 15	4'-Br	NH2	19	-	97	64
# 16	4'-Br	NHCH3	16	48	93	62
-	4'-Br	N(CH3)2	>>100	-	-27	2
# 8	H	NH2	64	81	98	61
# 7	4'-F	NH2	133	27	98	72
# 9	4'-Cl	NH2	>>100	29	98	65
# 15	4'-Br	NH2	19	23	97	64
# 14	4'-Br	OCH2CH3	>>25	33	-	60

\* Single topical dose of a 0.1 % drug solution/suspension 45 minutes prior to paracentesis

\*\*Diclofenac, also known as Voltaren Ophthalmic (TM), is used as a reference standard

\*\*\* Single topical dose of 0.1 % drug solution/ suspension 60 minutes prior to Iris/ciliary body isolation



The 3-benzoylphenylacetic acid derivative compounds of this invention are useful for controlling ophthalmic inflammatory disorders and ocular pain. Such disorders include, but are not limited to uveitis, scleritis, episcleritis, keratitis, surgically-induced inflammation and endophthalmitis.

5       The 3-benzoylphenylacetic acid derivatives may be formulated into a variety of topically administrable ophthalmic compositions, such as solutions, suspensions, gels or ointment.

10       Pharmaceutical compositions comprising compounds of Formula I in aqueous solution, optionally containing a preservative for multidose use and other conventionally employed ophthalmic adjuvants, including a salt entity to adjust the tonicity of solutions, can be employed. The most preferred form of delivery is by eye drops; however, formulations wherein the final specialty form is a gel or ointment can also be employed and formulated according to conventional technology. The ophthalmic compositions of the present invention will typically contain one or more compounds of Formula I in an  
15       amount of from about 0.001 to about 4.0% (w/v), preferably from about 0.01 to about 0.5% (w/v).

20       Further, additional therapeutic agents including steroids, such as, dexamethasone; antibiotics, such as gentamicin; anti-infectives, such as sulfonamides; and anti-allergics, such as antihistamines, may be added to supplement the ophthalmic compositions of the present invention.

25       The compositions may contain preservatives such as thimerosal, chlorobutanol, benzalkonium chloride, Onamer M, or chlorhexidine; buffering agents, such as phosphates, borates, carbonates and citrates; and thickening agents, such as, high molecular weight carboxy vinyl polymers, such as, the ones sold under the name of Carbopol which is a trademark of the B.F. Goodrich Chemical Company, hydroxyethylcellulose, or polyvinyl alcohol, for example.

The compositions are prepared by dissolving the various ingredients in the required amount of water with stirring to ensure that all the ingredients are dissolved. The aqueous compositions of the invention may be solutions, suspensions, or gels. After preparation of the solution, suspension, or gel the compositions are then packaged in dispensers suitable for delivery of the ophthalmic compositions.

The following examples of ophthalmic compositions typify the manner in which the invention may be practiced. The examples should be construed as illustrative, and not as a limitation upon the overall scope of the invention. The percentages are expressed on a weight/volume basis. "Active Agent" means one or more compounds of Formula I.

#### Formulation 1

Active agent	0.01 - 0.5%
Polysorbate 80	0.01%
Benzalkonium Chloride	0.01% + 10% excess
Disodium EDTA	0.1%
Monobasic Sodium Phosphate	0.03%
Dibasic Sodium Phosphate	0.1%
Sodium Chloride	q.s. 290-300 mOsm/Kg
pH adjustment with NaOH and/or HCl	pH 4.2 - 7.4
Water	q.s. 100%


25

## Formulation 2

	Active Agent	0.01 - 0.5%
	Hydroxypropyl Methylcellulose	0.5%
	Polysorbate 80	0.01%
5	Benzalkonium Chloride	0.01% + 5% excess
	Disodium EDTA	0.01%
	Dibasic Sodium Phosphate	0.2%
	Sodium Chloride	q.s. 290-300 mOsm/Kg
	pH adjustment with NaOH and/or HCl	pH 4.2 - 7.4
10	Water	q.s. 100%

We claim:

1. A 3-benzoylphenylacetic acid derivative of the formula:



W = O, H

R = H, C<sub>1-4</sub>(un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>

Y = OR<sup>5</sup>, NR<sup>5</sup>R<sup>6</sup>

R<sup>5</sup> = -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>2</sup>-(CH<sub>2</sub>)<sub>r</sub>A, -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>3</sup>-(CH<sub>2</sub>)<sub>r</sub>A'

r=2-6

r'=0-6

Z<sup>2</sup> = O, C=O, OC(=O), C(=O)NR<sup>3</sup>, NR<sup>3</sup>C(=O), -S(O)<sub>r2</sub>CH<sub>2</sub>-, S, CHOR<sup>3</sup>, NR<sup>3</sup>

Z<sup>3</sup> = nothing, -CHR<sup>4</sup>-, -CR<sup>4</sup>R<sup>4</sup>-

r<sup>2</sup>=1, 2

R<sup>3</sup>=H, C<sub>1-6</sub>(un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

A = H, OH, (un)substituted aryl (substitution as defined by X below),

(un)substituted heterocycle, -(CH<sub>2</sub>)<sub>r</sub>OR<sup>3</sup>

A' = OH, (un)substituted aryl (substitution as defined by X below),

(un)substituted heterocycle (substitution as defined by X below), -(CH<sub>2</sub>)<sub>r</sub>OR<sup>3</sup>

R<sup>4</sup> = C<sub>1-6</sub>(un)branched alkyl

R<sup>6</sup> = H, OR<sup>7</sup>

R<sup>7</sup> = H, C<sub>1-6</sub>(un)branched alkyl, (un)substituted aryl (substitution as defined by X below)

X and X' independently = H, F, Cl, Br, I, OR<sup>7</sup>, CN, OH, S(O)<sub>2</sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>, NO<sub>2</sub>

$m = 0-3$

$m' = 0-5$

$n^2 = 0-2$

2. The 3-benzoylphenylacetic acid derivative of Claim 1 wherein:

W = H

R = H, CH<sub>3</sub>

Y = NR<sup>5</sup>R<sup>6</sup>, -NHOH

R<sup>4</sup> = C<sub>1-4</sub> (un)branched alkyl

R<sup>5</sup> = -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>2</sup>-(CH<sub>2</sub>)<sub>r'</sub>-A, -(CH<sub>2</sub>)<sub>r</sub>-Z<sup>3</sup>-(CH<sub>2</sub>)<sub>r'</sub>-A'

r = 2-4

r' = 0-2

Z<sup>2</sup> = O

Z<sup>3</sup> = nothing

A = H

A' = (un)substituted aryl (substitution as defined by X below)

R<sup>6</sup> = H, OR<sup>7</sup>

R<sup>7</sup> = H, C<sub>1-2</sub> alkyl

X and X' independently = H, F, Cl, Br, CF<sub>3</sub>, S(O)<sub>n2</sub>R<sup>4</sup>, OR<sup>7</sup>


m = 0-2

m' = 0-3

n<sup>2</sup> = 0

3. The 3-benzoylphenylacetic acid derivative of Claim 1 wherein the derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-α(methylthio)-N-(2-methoxy)ethylacetamide, 2-Amino-3-(4-fluorobenzoyl)-α(methylthio)-N-3-(3,4-dimethoxyphenyl)propylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-(2-methoxy)ethyl phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-3-(3,4-dimethoxyphenyl)propyl phenylacetamide, and 3-Benzoyl-2-nitrophenyl-N-3-(3,4-dimethoxyphenyl)propyl acetamide.

4. A topically administrable, ophthalmic pharmaceutical composition for treating ophthalmic inflammatory disorders and ocular pain which comprises an anti-inflammatory-effective amount of a 3-benzoylphenylacetic acid derivative of the formula:



R = H, C<sub>1-4</sub> (un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>

Y = OR', NR''R'

R' = H (except when Y = OR'), C<sub>1-10</sub> (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A

n = 2-6

n' = 1-6

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR<sup>3</sup>,

NR<sup>3</sup>C(=O), S(O)<sub>n2</sub>, CHOR<sup>3</sup>, NR<sup>3</sup>

n<sup>2</sup> = 0-2

R<sup>3</sup> = H, C<sub>1-6</sub> (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH<sub>2</sub>)<sub>n</sub>OR<sup>3</sup>

R'' = H, OH, OR'

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)<sub>n2</sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>, NO<sub>2</sub>

R<sup>4</sup> = C<sub>1-6</sub> (un)branched alkyl


m = 0-3

m' = 0-5

W = O, H

29

5. The composition of Claim 4 wherein the 3-benzoylphenylacetic acid derivative is of the formula:



R = H, C<sub>1-2</sub> alkyl

Y = NR'R''

5 R' = H, C<sub>1-6</sub> (un)branched alkyl, -(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A

Z = nothing, O, CHOR<sup>3</sup>, NR<sup>3</sup>

R<sub>3</sub> = H

A = H, OH, (un)substituted aryl (substitution as defined by X below)

X and X' independently = H, F, Cl, Br, CN, CF<sub>3</sub>, OR', SR<sup>4</sup>, R<sup>4</sup>

10 R'' = H

R<sup>4</sup> = C<sub>1-4</sub> (un)branched alkyl

m = 0-2

m' = 0-2

W = H

15 n = 2-4

n' = 0-3

6. The composition of Claim 4 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-α-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-α-(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-α-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-5-chloro-α-(methylthio)-phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-α(methylthio)-N-(2-methoxy)ethylacetamide, 2-Amino-3-(4-
- 20


fluorobenzoyl)- $\alpha$ -(methylthio)-N-3-(3,4-dimethoxyphenyl)propylacetamide, 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-5-chlorophenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-(2-methoxy)ethyl phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-3-(3,4-dimethoxyphenyl)propyl phenylacetamide, 3-Benzoyl-2-nitrophenyl-N-3-(3,4-dimethoxyphenyl)propyl acetamide, Ethyl 2-Amino-3-(4-bromobenzoyl)benzene acetate, 2-Amino-3-(4-bromobenzoyl)-phenylacetamide, and 2-Amino-3-(4-bromobenzoyl)-N-methyl phenylacetamide.

- 10      7.      The composition of Claim 6 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-5-chloro- $\alpha$ -(methylthio)-phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-5-chlorophenylacetamide, and 2-Amino-3-(4-bromobenzoyl)-phenylacetamide.
- 15      8.      The composition of Claim 7 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.
- 20      9.      The composition of Claim 4 wherein the amount of 3-benzoylphenylacetic acid is from about 0.001 to about 4.0% (w/v).
- 25      10.      The composition of Claim 9 wherein the amount of 3-benzoylphenylacetic acid is from about 0.01 to about 0.5% (w/v).
11.      A method of treating ophthalmic inflammatory disorders and ocular pain which comprises topically administering to the eye a pharmaceutical composition



31

comprising an anti-inflammatory-effective amount of a 3-benzoylphenylacetic acid derivative of the formula:



$R = H, C_{1-4}$  (un)branched alkyl,  $CF_3$ ,  $SR^4$

$Y = OR', NR''R'$

$R' = H$  (except when  $Y = OR'$ ),  $C_{1-10}$  (un)branched alkyl, (un)substituted (substitution as defined by  $X$  below), (un)substituted heterocycle (substitution as defined by  $X$  below),  $-(CH_2)_nZ(CH_2)_nA$

$n = 2-6$

$n' = 1-6$

$Z = \text{nothing}, O, C=O, OC(=O), C(=O)O, C(=O)NR^3, NR^3C(=O), S(O)_{n^2}, CHOR^3, NR^3$

$n^2 = 0-2$

$R^3 = H, C_{1-6}$  (un)branched alkyl, (un)substituted aryl (substitution as defined by  $X$  below), (un)substituted heterocycle (substitution as defined by  $X$  below)

$A = H, OH$ , optionally (un)substituted aryl (substitution as defined by  $X$  below), (un)substituted heterocycle (substitution as defined by  $X$  below),  $-(CH_2)_nOR^3$

$R'' = H, OH, OR'$

$X$  and  $X'$  independently =  $H, F, Cl, Br, I, OR', CN, OH, S(O)_{n^2}R^4, CF_3, R^4, NO_2$


$R^4 = C_{1-6}$  (un)branched alkyl

$m = 0-3$

$m' = 0-5$

$W = O, H$

12. The method of Claim 11 wherein the 3-benzoylphenylacetic acid derivative is of the formula:



R = H, C<sub>1-2</sub> alkyl

Y = NR'R''

5 R' = H, C<sub>1-6</sub> (un)branched alkyl, -(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A

Z = nothing, O, CHOR<sup>3</sup>, NR<sup>3</sup>

R<sub>3</sub> = H

A = H, OH, (un)substituted aryl (substitution as defined by X below)

X and X' independently = H, F, Cl, Br, CN, CF<sub>3</sub>, OR', SR<sup>4</sup>, R<sup>4</sup>

10 R'' = H

R<sup>4</sup> = C<sub>1-4</sub> (un)branched alkyl

m = 0-2

m' = 0-2

W = H

15 n = 2-4

n' = 0-3

13. The method of Claim 11 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-α-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-α-(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-α-(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-5-chloro-α-(methylthio)-phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-α(methylthio)-N-(2-methoxy)ethylacetamide, 2-Amino-3-(4-fluorobenzoyl)-α(methylthio)-N-3-(3,4-dimethoxyphenyl)propylacetamide, 2-Amino-
- 20

3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-5-chlorophenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-(2-methoxy)ethyl phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-N-3-(3,4-dimethoxyphenyl)propyl phenylacetamide, 3-Benzoyl-2-nitrophenyl-N-3-(3,4-dimethoxyphenyl)propyl acetamide, Ethyl 2-Amino-3-(4-bromobenzoyl)benzene acetate, 2-Amino-3-(4-bromobenzoyl)-phenylacetamide, and 2-Amino-3-(4-bromobenzoyl)-N-methyl phenylacetamide.

14. The method Claim 13 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)- $\alpha$ -(n-propylthio)-phenylacetamide, 2-Amino-3-benzoyl-5-chloro- $\alpha$ -(methylthio)-phenylacetamide, 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide, 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-5-chlorophenylacetamide, and 2-Amino-3-(4-bromobenzoyl)-phenylacetamide.
15. The method of Claim 14 wherein the 3-benzoylphenylacetic acid derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide, 2-Amino-3-benzoyl-phenylacetamide and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.
16. The method of Claim 11 wherein the amount of 3-benzoylphenylacetic acid is from about 0.001 to about 4.0% (w/v).
17. The method of Claim 16 wherein the amount of 3-benzoylphenylacetic acid is from about 0.01 to about 0.5% (w/v).

## INTERNATIONAL SEARCH REPORT

 Intern: J Application No  
 PCT/US 95/07187

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/165 A61K31/215 C07C237/20 C07C233/33 C07C323/60

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,4 910 225 (OGAWA ET AL.) 20 March 1990 cited in the application see claim 1 ---	1-17
Y	DE,A,30 26 402 (SYNTEX CORP.) 4 February 1982 see page 10, line 15 - line 20 see page 8, line 34 ---	1-17
X	US,A,4 683 242 (POSER) 28 July 1987 cited in the application see claim 1 --- -/--	4-10

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

29 September 1995

Date of mailing of the international search report

13. 10. 95

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Gerli, P

## INTERNATIONAL SEARCH REPORT

Intern: Application No  
PCT/US 95/07187

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 126 635 (WELSTEAD ET AL.) 21 November 1978 cited in the application see column 20, line 47 - line 56 see column 1, line 22 - line 37 see column 1, line 56 - line 60 ---	4-10
X	US,A,4 313 949 (SHANKLIN ET AL.) 2 February 1982 cited in the application see column 13, line 44 - column 14, line 35 see column 2, line 3 - line 19 ---	4-10
X	US,A,4 182 774 (WELSTEAD ET AL.) 8 January 1980 cited in the application see column 22, line 68 - column 24, line 19 -----	4-10

# INTERNATIONAL SEARCH REPORT

I. International application No.

PCT/US 95/07187

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
REMARK: Although claims 11-17 are directed to a method of treatment of  
(diagnostic method practised on) the human/animal body the search has been  
carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such  
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: Application No

PCT/US 95/07187

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4910225	20-03-90	AU-B- 2878689	27-07-89
		EP-A, B 0326915	09-08-89
		ES-T- 2052784	16-07-94
		JP-A- 2124817	14-05-90
DE-A-3026402	04-02-82	NONE	
US-A-4683242	28-07-87	AU-B- 596813	17-05-90
		AU-B- 6444786	30-04-87
		DE-A- 3683350	20-02-92
		EP-A, B 0221753	13-05-87
		IE-B- 59229	26-01-94
		JP-A- 62126124	08-06-87
US-A-4126635	21-11-78	US-A- 4045576	30-08-77
		AT-B- 329542	10-05-76
		AT-B- 347433	27-12-78
		AU-B- 1614276	26-01-78
		AU-B- 5584673	21-11-74
		AU-B- 530940	04-08-83
		AU-B- 6181480	08-01-81
		BE-A- 799611	17-09-73
		BE-A- 837154	16-04-76
		CA-A- 1012979	28-06-77
		CA-A- 1087205	07-10-80
		CA-A- 1103679	23-06-81
		CH-A- 577461	15-07-76
		DE-A- 2324768	29-11-73
		DE-A- 2636582	24-02-77
		FR-A, B 2184934	28-12-73
		GB-A- 1432576	22-04-76
		GB-A- 1521097	09-08-78
		JP-C- 1136375	28-02-83
		JP-A- 52023052	21-02-77
		JP-B- 57026585	05-06-82
		JP-C- 876459	10-08-77
		JP-A- 49041349	18-04-74
		JP-B- 52003381	27-01-77
		JP-A- 55000349	05-01-80
		NL-A- 7306833	20-11-73

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern al Application No

PCT/US 95/07187

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4126635		SE-B- 400966 US-A- 4182774	17-04-78 08-01-80
US-A-4313949	02-02-82	AT-B- 374170 AU-B- 532359 AU-B- 6211680 BE-A- 885393 CA-A- 1128512 CH-A- 646138 DE-A- 3035688 FR-A, B 2465710 GB-A, B 2059963 JP-B- 1041616 JP-C- 1559426 JP-A- 56057751 LU-A- 82797 NL-A- 8005346 SE-B- 448626 SE-A- 8006668	26-03-84 29-09-83 02-04-81 16-01-81 27-07-82 15-11-84 16-04-81 27-03-81 29-04-81 06-09-89 16-05-90 20-05-81 10-05-82 30-03-81 09-03-87 27-03-81
US-A-4182774	08-01-80	US-A- 4045576 AT-B- 329542 AT-B- 347433 AU-B- 1614276 AU-B- 5584673 AU-B- 530940 AU-B- 6181480 BE-A- 799611 BE-A- 837154 CA-A- 1012979 CA-A- 1087205 CA-A- 1103679 CH-A- 577461 DE-A- 2324768 DE-A- 2636582 FR-A, B 2184934 GB-A- 1432576 GB-A- 1521097 JP-C- 1136375 JP-A- 52023052	30-08-77 10-05-76 27-12-78 26-01-78 21-11-74 04-08-83 08-01-81 17-09-73 16-04-76 28-06-77 07-10-80 23-06-81 15-07-76 29-11-73 24-02-77 28-12-73 22-04-76 09-08-78 28-02-83 21-02-77



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/07187

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4182774		JP-B- 57026585	05-06-82
		JP-C- 876459	10-08-77
		JP-A- 49041349	18-04-74
		JP-B- 52003381	27-01-77
		JP-A- 55000349	05-01-80
		NL-A- 7306833	20-11-73
		SE-B- 400966	17-04-78
		US-A- 4126635	21-11-78
-----			